CPBM's two antiviral products in combination are currently the only effective therapy for treating chronic hepatitis C around the world, a market that is worth over $4 billion per year. CPBM's C-Virin and CPegferon, will be manufactured in FDA inspected, off-shore production facilities and offered at generic drug pricing. CPBM plans to have its generic antiviral products ready for sales in developing countries and outside the major markets in approximately one year from its initiation, and approximately 18-24 months thereafter for approvals in the U.S., Europe, and Japan.

In our opinion, this gives investors an opportunity to get involved in the stock before it hits the radar screens of larger investors. Shares of companies that are involved in hepatitis C research have been among some of Wall Street's top performers, primarily as a result of the tremendous opportunity for its cure and prevention. The number of potential patients in need of treatment represents a large and profitable market, since an estimated 270-300 million people worldwide are infected with hepatitis C. 

There is no cure for liver disease caused by chronic hepatitis C infection; the current treatment is very expensive and the therapy with Ribavirin and pegylatedinterferon is only effective in about 50-60% of all cases of hepatitis C. CPBM intends to find more effective therapeutics for this disease and has acquired an exclusive worldwide license from the National Institutes of Health (NIH) for the development of a patented vaccine to prevent and stop hepatitis C infections. 

The vaccine to prevent hepatitis C was developed in the USA at the NIH and has had over $10 million spent on it to date via private investors and grants, has successfully completed animal and primate studies, and is readied for human testing. The World Health Organization states that CPharma's Hep C vaccine is the most likely approach to be successful. Further, C-Pharma will also acquire an additional 8 other patents protecting a technology platform for developing products to treat obesity, Alzheimer's Disease, rheumatoid arthritis and other chronic diseases. These patents represent a valuable partnering opportunity for CPBM along with potential in-house pipeline product development. 

Hepatitis C

Hepatitis C is an infectious disease affecting the liver that can progress to scarring of the liver (fibrosis), and advanced scarring (cirrhosis) which is generally apparent after many years. In some cases, those with cirrhosis will go on to develop liver failure or other complications of cirrhosis, including liver cancer. The hepatitis C virus is spread by blood-to-blood contact. Most people have few, if any symptoms after the initial infection, yet the virus persists in the liver in about 85% of those infected. Persistent infection can be treated with medication, peginterferon and Ribavirin being the standard-of-care therapy. 51% are cured overall. Those who develop cirrhosis or liver cancer may require a liver transplant, and the virus universally recurs after transplantation. Unlike hepatitis A and B, there is currently no vaccine to prevent hepatitis C infection.

Infection with the highly contagious hepatitis C virus ("HCV") has grown into a global epidemic, with, as we mentioned previously, an estimated 270-300 million people worldwide infected with the virus, which is about 4% of the world's population effort to contain the spread of this virus, the death rate from hepatitis C has surpassed that of HIV/AIDS, and will continue to get worse. 

Tremendous Profit Potential

In our opinion, there is no better way to make money in the stock market than by investing in companies that make people's lives better. We encourage investors to contact CPBM directly and ask if there are opportunities available for private investment in the company. Since the stock is closely held, and somewhat illiquid, in our opinion, this could be a win-win situation. Investors could get to invest directly into a company with the potential for huge stock market profits, and CPBM gets additional capital to work its business plan. This does not mean, however, that you should not consider buying stock in the open market. Shares purchased from a company are usually restricted from resale for a period of time, while shares purchased in the open market can be bought and sold at will. It is simply an option we would like to remind our subscribers of.

The market for hepatitis C stocks is hot. There are not a lot of true players in the market. We urge you to look at the charts and news of the following companies, so you can share the enthusiasm we have for the potential of CPBM. You will see these stocks are news and event driven, as we believe CPBM will also be.

Hepatitis C Stocks

Human Genome Sciences (NASDAQ: HGSI) is developing a drug, Albuferon, that patients in a midstage trial of it are reporting better quality of life although it is at an early stage. They agreed to jointly market Albuferon with Swiss pharmaceutical giant Novartis, but there is a risk that the late stage clinical trials could show Albuferon not to be as effective as investors had initially hoped. 

Idenix Pharmaceuticals (NASDAQ: IDIX) has partnered with Novartis on its drug, NM283. The drug has modest potency but is undergoing a trial in combination interferon and ribavirin that may show better results. Roche has a competing drug that may be more potent but it has to be given in higher doses. 

Intermune (NASDAQ: ITMN) of Brisbane, CA has partnered with Swiss pharmaceutical titan Roche on several of its drugs. There have been mixed results and the Company is involved in an on-going Phase 2b study. 
Schering-Plough (NYSE: SGP) is an established player in the treatment of Hepatitis C with a few different drugs which brought in 750 million in sales last year. They have a few new drugs that are in development right now, but, in our opinion, even a breakthrough drug will have little impact on the stock price, since SGP is a large, diversified pharmaceutical company.
ViroPharma (NASDAQ: VPHM) of Exton, PA announced in August that data from an early stage trial of its drug reduced the virus 99% after 14 days of treatment in combination with interferon.

Vertex Pharmaceuticals (NASDAQ: VRTX) is one of our winners with a call from $14.00 to $42.00 a few years ago. VRTX is the leader in the pack for drugs treating the virus. The small to mid-stage clinical trial results have been strong and the stock has quadrupled over the past 2 years on optimism about its drug. VRTX is a great example of the type of profits that are available in this market.

In our opinion, a smaller player, like CPBM, offers more bang for your buck and could easily wind up laying the ever elusive ten-bagger on our doorstep. We want our subscribers to get involved in CPBM, whether it is through the company directly, or by purchasing shares in the open market.

Management

The key to delivering results to shareholders in any small-cap company is honest, hard working, competent management. In our opinion these factors are among one of the key characteristics of a quality growth company and a foremost identifier.

CPBM’s management team, advisors and consultants possess a deep knowledge of the Company’s products, the markets and indications, and have strong start-up company management experience and therefore we expect they can deliver on the business plan.

Garth Likes, Founder, President, Chief Executive Officer and Director of C-Pharma, is the former founder and CEO of several public companies and brings 30 years of experience to successfully navigate this new Company through financings and corporate operations. Mr. Likes also currently sits on the board of Directors and Audit Committee of Lab Research (TSE: LRI) and is a member of the board of 2 other private biotech companies.

Dr. Joseph Sinkule, Founder, Consultant to CPharma, is a serial entrepreneur and a 28-year biotech veteran with extensive biotech startup experience. Dr. Sinkule has taken several drug and recombinant protein products from discovery thru FDA approval and licensure. He was Sr. VP of R&D at a NASDAQ-listed biotech company and Director of Clinical Research at Immunex. Dr. Sinkule also founded five other biotech companies and currently serves on the Board of 4 healthcare companies.

Seth Goldblum, MBA, Chief Business Officer of CPharma, is a biotech executive with 20 years of business development deal-making, finance and corporate management experience, particularly in the vaccine area. Mr. Goldblum and Mr. Likes will be key contributors in the finance and corporate partnering areas. Mr. Goldblum will have primary responsibility for structuring an agreement to out-license the preventive indication of the HCV vaccine to one of the major vaccine company. 

William Gannon M.D., MBA and Physician, Chief Medical Officer of C-Pharma, will manage the day-today activities of outsourcing while overseeing product development and the contractual arrangements with CROs, CSOs, and CMOs required to make, test, and obtain regulatory approvals of CPBM’s product candidates.

Business Strategy

Lower cost anti-viral drugs for treatment of hepatitis are needed to slow the growing epidemic of hepatitis C infections which cause over 75%-80% of liver disease around the world. Ribavirin and interferon-alpha (especially pegylated interferon-alpha) are the mainstays of anti-viral therapy against hepatitis C, but these drugs are unaffordable by most patients infected with the virus, costing several thousands of dollars per month for up to 48 months of therapy. CPBM intends to have the active ingredients manufactured for the Company by “off-shore” suppliers that comply with FDA and European regulatory processes. The regulatory approvals for marketing its own branded anti-viral drug products are expected to occur within 6-12 months of the regulatory submissions in countries such as Brazil, Mexico and Argentina and within 12-18 months in countries like the U.S. and the countries of the European Union. 

CPBM intends to invest revenues from near-term sales of anti-viral drugs into its preventative vaccine development program, and to investigate new and better anti-viral therapies. 

During the initial phases of operations, in order to save money and time, CPBM intends to outsource GMP production, clinical trials management, and global regulatory submissions to contract research organizations. Additionally, CPBM intends to utilize a contract marketing and sales organization with experience in the anti-viral market to launch and sell its anti-viral products, once approved by the regulatory authorities. Longer-term upside potential for the Company is the patented preventative vaccine to stop hepatitis C infections. 

CPBM’s near-term plans are to submit market applications in multiple countries for the Company's anti-viral drugs and complete Phase I safety, immunology & efficacy studies of the hepatitis C vaccine in humans. In our opinion, this will create value as CPBM achieves major developmental milestones in the next 18-24 months, generates revenue from the sale of anti-viral drugs, and provides proof in humans that the VLP vaccine immunization leads to the development of neutralizing antibodies, which attack the hepatitis C virus and prevent infection. Based on CPBM's ability to attract a corporate partner and obtain financing, it will continue to advance the development of other anti-viral pipeline products and to begin Phase II efficacy studies of the VLP vaccine as a potential anti-viral immunotherapy for treating chronic HCV infection. An antibody product derived from VLP vaccine inoculation will be evaluated in patients undergoing liver transplantation to prevent or significantly graft reinfection. 

Summary

There is no new research activity required to get CPBM’s first products to market. Its generic-priced Ribavirin and pegylated-interferon will simply take a part of the $4 Billion established Ribavirin and interferon name brand market from Roche and Schering-Plough.

Additionally, the hepatitis C vaccine was invented in the USA at the NIH and has had over $10 million spent on it to date via private investors and grants. The Company has successfully completed animal and primate studies, and is readied for human testing. Once again, the World Health Organization states that CPBN’s Hep C vaccine is the most likely approach to be successful.

Investors can purchase shares in the open market by entering trades using the ticker symbol "CPBM". However as only a handful of people know about the Company, the stock is not heavily traded. As we mentioned previously, investors can also invest in Cyplasin by purchasing shares directly from the company via an ongoing private placement. 


For additional information contact:
Garth Likes:
President/CEO
Phone: 780.990.4539
email: glikes@c-pharma.net
or
Roderick Christie
Investor Relations
Phone 702.490.0481
Email: rwmcconsulting@hotmail.com